NEW YORK (GenomeWeb News) – Affymetrix today announced a deal with Massachusetts General Hospital to co-develop cancer biomarker tests using Affy's QuantiGene ViewRNA Assay platform.

As part of the deal, Affy has the commercialization rights to new tests resulting from the collaboration. Other terms were not disclosed.

The QuantiGene ViewRNA Assay is an in situ hybridization assay with single-transcript in single-cell detection capability. The platform is for research-use only.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.